BerGenBio has met the initial efficacy endpoint in its Phase II trial of BGB324 (bemcentinib) selective AXL inhibitor in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).

The BGBC004 trial is designed to investigate the hypothesis that selective AXL inhibition with once-daily oral small molecule bemcentinib may reverse and prevent resistance to erlotinib, a therapy targeting constitutively active EGFR signalling.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial enrols patients who have progressed on an approved epidermal growth factor receptor (EGFR) inhibitor, with activating EGFR mutations across three arms, A, B, and C.

Arm A of the trial seeks to determine the daily dose of bemcentinib that can be safely given in combination with erlotinib to patients who have received prior erlotinib therapy. The arm is finished and recommendation for a Phase II dose has been set-up.

“The trial’s Arm C is expected to examine the ability of bemcentinib to prevent acquired resistance to EGFR targeted therapy when given in combination with erlotinib first-line.”

Arm B features a Simon-like two-stage design to assess the ability of bemcentinib to restore sensitivity to EGFR targeted therapy when given in combination with erlotinib in patients who have progressed on prior therapy with an approved EGFR inhibitor and are negative for the T790M mutation.

This arm has been able to meet the newly announced endpoint that demonstrates an overall disease control rate of 33% in patients who completed at least one cycle of treatment.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The result offers a preliminary proof of concept that bemcentinib can restore sensitivity to EGFR targeted therapy in some patients.

The trial’s Arm C is expected to examine the ability of bemcentinib to prevent acquired resistance to EGFR targeted therapy when given in combination with erlotinib first-line.

Recruitment in this arm is still going on, with interim results expected to be released during mid-2018.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now